biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech
Nanjing Legend Biotech Co.
Legend Biotech is a biotech organization headquartered in Somerset, USA. Primary therapeutic focus areas include Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Autoimmune Diseases, Multiple Myeloma, Gastric Ca
Company details
- Status
- Public
- HQ
- 2101 Cottontail Lane, Somerset, New Jersey 08873, US
- Employees
- 2,457
- Programs
- 36
- Drugs
- 17
- Patents
- 26
Quick answer
Legend Biotech is a biotech organization headquartered in Somerset, USA. Primary therapeutic focus areas include Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Autoimmune Diseases, Multiple Myeloma, Gastric Cancer, Systemic Lupus Erythematosus (SLE). NovaPharmaNews links 36 clinical program(s), 0 drug profile(s), and 26 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (31), phase 2 (2).
Company snapshot
Legend Biotech is a global, commercial-stage biotechnology company developing and manufacturing novel therapies. We explore and apply innovative technologies to deliver cutting-edge options for patients around the world. Our corporate headquarters is located in Somerset, NJ, and our manufacturing footprint includes facilities in the United States, China and the Belgium.
- 36 active pipeline program(s) linked via ClinicalTrials.gov.
- 26 US patent(s) indexed to this assignee profile.
- 36 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Nanjing Legend Biotech. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO
- approval
Legend Biotech's In Vivo CAR-T Data Sparks Stock Surge: A Catalyst Tracking Analysis
- deal
Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
Recent coverage
Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner
Legend Biotech shares soared over 40% after disclosing early in vivo CAR-T data in Non-Hodgkin's lymphoma. This analysis explains the development, implications for pharma teams, and key milestones to track.
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
Legend Biotech's In Vivo CAR-T Data Sparks Stock Surge: A Catalyst Tracking Analysis
Legend Biotech's stock experienced a significant surge following the release of initial in vivo CAR-T cell therapy data. This development signals a potential shift in the CAR-T landscape, with implications for manufacturing, accessibility, and competitive dynamics.
Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO
Legend Biotech has presented significant new data at ASCO 2026, showcasing updated survival and safety results for its multiple myeloma therapy CARVYKTI from the CARTITUDE-4 study. The company also unveiled first-in-human data for its investigational CAR-T cell therapy, LB2102, targeting solid tumors.
Top assets
Lead pipeline drugs
- approved
- Marketed / approved
- Marketed / approved
- approved
Active clinical programs
- Phase 2
- Phase 2
- Phase 1
- Phase 1
Momentum
Proprietary activity score for Nanjing Legend Biotech.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Nanjing Legend Biotech.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Nanjing Legend Biotech?
-
Is Nanjing Legend Biotech publicly traded?
-
What drugs does Nanjing Legend Biotech develop or market?
-
What are the latest developments for Nanjing Legend Biotech?
-
What therapeutic areas does Nanjing Legend Biotech focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.